USFDA approves Roche’s Tecentriq (Atezolizumab) as Adjuvant Treatment for Non- small Cell Lung Cancer.
Keypoints USFDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early NSCLC Tecentriq treatment reduced the risk of disease recurrence…